Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$18.64|
|52 Week High||HK$13.00|
|52 Week Low||HK$25.35|
|1 Month Change||-9.95%|
|3 Month Change||0.65%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||29.27%|
Recent News & Updates
What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Every investor in Jacobio Pharmaceuticals Group Co., Ltd. ( HKG:1167 ) should be aware of the most powerful shareholder...
|1167||HK Biotechs||HK Market|
Return vs Industry: Insufficient data to determine how 1167 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 1167 performed against the Hong Kong Market.
Stable Share Price: 1167 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 1167's weekly volatility (8%) has been stable over the past year.
About the Company
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company’s lead drug development programs include two clinical-stage allosteric SHP2 inhibitors comprising JAB-3068 and JAB-3312 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also developing JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor to treat various RB1-deficient tumors; JAB-24000, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations.
Jacobio Pharmaceuticals Group Fundamentals Summary
|1167 fundamental statistics|
Is 1167 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1167 income statement (TTM)|
|Cost of Revenue||CN¥97.25m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.09|
|Net Profit Margin||-154.30%|
How did 1167 perform over the long term?See historical performance and comparison
Is Jacobio Pharmaceuticals Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1167's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1167's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1167 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.
PE vs Market: 1167 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1167's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1167 is overvalued based on its PB Ratio (6.6x) compared to the HK Biotechs industry average (4x).
How is Jacobio Pharmaceuticals Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1167 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1167 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1167 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1167's revenue (35.8% per year) is forecast to grow faster than the Hong Kong market (12.5% per year).
High Growth Revenue: 1167's revenue (35.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1167's Return on Equity is forecast to be high in 3 years time
How has Jacobio Pharmaceuticals Group performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 1167 is currently unprofitable.
Growing Profit Margin: 1167 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1167's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1167's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1167 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50%).
Return on Equity
High ROE: 1167 has a negative Return on Equity (-46.81%), as it is currently unprofitable.
How is Jacobio Pharmaceuticals Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1167's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥74.8M).
Long Term Liabilities: 1167's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥4.8M).
Debt to Equity History and Analysis
Debt Level: 1167 is debt free.
Reducing Debt: 1167 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 1167 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 1167 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 89.8% per year.
What is Jacobio Pharmaceuticals Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1167's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1167's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1167's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1167's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1167's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yinxiang Wang (56 yo)
Dr. Yinxiang Wang serves as Consultant at Shining Capital. He is an Executive Chairman at Jacobio Pharmaceuticals Co. Ltd. since August 20, 2020.Dr. Wang has been Director at Jacobio Pharmaceuticals Co. L...
Experienced Management: 1167's management team is considered experienced (2 years average tenure).
Experienced Board: 1167's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: 1167 only recently listed within the past 12 months.
Jacobio Pharmaceuticals Group Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Jacobio Pharmaceuticals Group Co., Ltd.
- Ticker: 1167
- Exchange: SEHK
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$14.380b
- Shares outstanding: 771.46m
- Website: https://www.jacobiopharma.com
Number of Employees
- Jacobio Pharmaceuticals Group Co., Ltd.
- Building F2
- No. 88 Kechuang 6th Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 16:59|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.